FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL	OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Dunn Judith						2. Issuer Name and Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [FULC]							elationship o eck all application Director	able)) Perso	on(s) to Issu 10% Ov Other (s	ner	
(Last)	`	irst) IERAPEUTICS,	(Middle) INC.		3. Date of Earliest Transaction (Month/Day/Year) 01/19/2022							below)						
26 LANI	OSDOWNE	ESTREET		4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. In	6. Individual or Joint/Group Filing (Check Applicable					
(Street)	IDGE M	IA	02139							Line								
(City)	(S	tate)	(Zip)										. 0.0011					
		Та	ble I - Non-I	Derivati	ve Se	ecuritie	s Ac	quired, C	Disp	osed o	of, or Be	neficially	/ Owned					
Date				. Transaction ate Month/Day/	Execution Date,		Code (Instr.			5. Amoun Securities Beneficia Owned Fo	s Formally (D) of ollowing (I) (I		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code V Amount (A) or (D)			r Price	Transacti (Instr. 3 a	n(s) id 4)			(
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ercise (Month/Day/Year) of ative	3A. Deemed Execution Date, if any (Month/Day/Year)	Code		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(e S Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)		
				Code	v	(A) (D)		Date Ex Exercisable Da		epiration ate	Title	Amount or Number of Shares		(Instr. 4)				
Stock Option (right to buy)	\$12.69	01/19/2022		A		140,890		(1)	01	/18/2032	Common Stock	140,890	\$0.00	140,89	00	D		

Explanation of Responses:

1. This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service.

Remarks:

President, Research & Development

/s/ Peter Thomson, as attorneyin-fact for Judith A. Dunn

01/21/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.